April 25 (Reuters) - Bausch Health Companies Inc BHC.TO :
* FDA APPROVES BAUSCH HEALTH'S DUOBRII (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION 0.01%/0.045% FOR PLAQUE PSORIASIS IN ADULTS
* BAUSCH HEALTH COMPANIES INC - DUOBRII IS EXPECTED TO BE AVAILABLE IN JUNE 2019
* BAUSCH HEALTH COMPANIES INC - DUOBRII LOTION IS PRICED AT $825 FOR A SUPPLY OF A 100-GRAM TUBE
* BAUSCH HEALTH COMPANIES INC - DUOBRII LOTION FOR COMMERCIALLY INSURED PATIENTS WILL HAVE A CO-PAY BETWEEN $25 AND $40